Figure S2 from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

Authors :: Sabine C. Linn
Carlos Caldas
Javier Cortès
William Gallagher
Cristina Saura
René Bernards
Aurelia de Vries Schultink
Margaret Schot
Petra Nederlof
Else Platte
Hilde Rosing
José-Manuel Perez-Garcia
Emma Beddowes
Maurizio Callari
Harm van Tinteren
Sanjeev Kumar
Constanza Linossi
Erik van Werkhoven
Greig Dougall
Anne-Laure Vallier
Javier Garcia-Corbacho
Ingrid A.M. Mandjes
Mariette Schrier
Meiling Gao
Karin Beelen
Mafalda Oliveira
Annelot G.J. van Rossum
Richard D. Baird
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Pharmacokinetics: Z-endoxifen levels per taselisib dose level

Full Text Access

Tools